
Boehringer Ingelheim Opens New R&D Center in Basel
NBE Therapeutics (NBE), a wholly owned subsidiary of Boehringer Ingelheim, officially opened its new ADC R&D facility in Basel.
NBE Therapeutics (NBE), a wholly owned subsidiary of Boehringer Ingelheim, officially opened its new ADC R&D facility in Basel.
On Wednesday, China’s Wanhua Chemical opened its R&D center in Cornellà de Llobregat near Barcelona, Spain, providing technical support and services to downstream customers in fine chemicals and materials on topics like product performance, application methods, and raw material selection.
Manual experiment monitoring and data capture is still the status quo in most biotech and pharma labs, compromising efficiency and project timescales. But there is a better way.
The Spanish computational chemistry start-up Nextmol (Bytelab Solutions), a spin-off from the Barcelona Supercomputing Centre, offers a software-as-a-service (SaaS) platform that accelerates research and innovation in sustainable specialty chemicals through “in silico” experiments using molecular modeling and artificial intelligence (AI).
US biopharma Ultragenyx Pharmaceutical has opened a gene therapy manufacturing facility in Bedford, Massachusetts, USA. The company said it is one of the first in the US with complete end-to-end gene therapy capabilities, from R&D through to therapeutic production at scale.
From agrochemicals to textiles: the broad range of use of surfactants will be at the center of interest of the 11th World Surfactants Congress, CESIO 2019 in Munich
Swiss-based, globally oriented CDMO Siegfried has broken ground or its new global Research and Development (R&D) Center for Drug Substances at its site in Evionnaz, Switzerland, which the company describes as a “key pillar” in its related network.
Bayer is looking to spend $1 billion on drug research and development in the United States during 2023 as part of a plan to double its sales in the country by the end of the decade.
Danish pharma Novo Nordisk is expanding its R&D capabilities in Boston, Massachusetts, US, which will lead to the closure of a facility in Indianapolis and a restructuring of its Seattle operations.
Danish companies Novozymes and Chr. Hansen have agreed to merge, in a move they termed a perfect match that will create a global leader in biosolutions.
US chemical producer Ashland is expanding its production and R&D site at the National Science Park in Mullingar, Ireland, which makes its Viatel-branded bioresorbable polymer. The upgrade, begun this summer, is expected to complete in 2024.
Swiss chemical, pharmaceutical and life sciences companies help drive research around the world, and major players have research activities in the US, Singapore, Japan, as well as EU facilities in the United Kingdom and Germany. But do not underestimate the role of the domestic regional clusters and industrial sites.
Virtually all areas of our lives would be inconceivable without products that come directly or indirectly in contact with chemical production: It affects the modern office environment, our private lives and thus our well-being and life fulfilment including health, leisure and personal protection.